|
|
Article: Biomira and Merck KGaA Announce Phase IIb BLP25 Liposomal Vaccine Trial in Non-Small Cell Lung Cancer Shows Evidence of a 4.4 Month Overall Improvement in Survival.
- Article from:
- PR Newswire
- Article date:
- April 2, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biomira Inc. (TSX:BRA) and Merck KGaA of Darmstadt, Germany, said today preliminary results from a randomized, open-label Phase IIb trial of BLP25 liposomal vaccine (L BLP25) in patients with Stage IIIb and IV non- small cell lung cancer (NSCLC) indicate that the median survival of those patients on the vaccine arm was 4.4 months longer than those on the control arm. Although not statistically significant, the overall median survival is 17.4 months for patients on the vaccine arm versus 13 months for the patients on the control arm.
Importantly, the observed two-year survival for patients with locoregional Stage IIIb disease is 60 per cent for the vaccine arm ...